Poxel SA
π«π·France
- Country
- π«π·France
- Ownership
- Public
- Established
- 2009-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.poxelpharma.com
Study to Assess the Safety, Tolerability, and Pharmacokinetics of PXL770 in Healthy Subjects.
- First Posted Date
- 2022-07-01
- Last Posted Date
- 2022-07-01
- Lead Sponsor
- Poxel SA
- Target Recruit Count
- 16
- Registration Number
- NCT05441904
- Locations
- π¬π§
HMR, London, Nw10, United Kingdom
Study to Assess PXL065 in Subjects With Adrenomyeloneuropathy (AMN) Form of X-linked Adrenoleukodystrophy (X-ALD or ALD)
- First Posted Date
- 2022-01-20
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Poxel SA
- Target Recruit Count
- 12
- Registration Number
- NCT05200104
Study to Assess PXL770 in Subjects With Adrenomyeloneuropathy (AMN) Form of X-linked Adrenoleukodystrophy (X-ALD or ALD)
- First Posted Date
- 2021-12-06
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Poxel SA
- Target Recruit Count
- 24
- Registration Number
- NCT05146284
Study of PXL065 in Patients With Nonalcoholic Steatohepatitis (NASH)
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2020-03-25
- Last Posted Date
- 2023-08-29
- Lead Sponsor
- Poxel SA
- Target Recruit Count
- 117
- Registration Number
- NCT04321343
- Locations
- πΊπΈ
Study site 30, Clarksville, Tennessee, United States
πΊπΈStudy site 04, Huntington Park, California, United States
πΊπΈStudy site 09, Edinburg, Texas, United States
A Study to Assess the Pharmacokinetics of PXL770 After 4 Weeks of Treatment in Subjects With NAFLD
- First Posted Date
- 2019-05-15
- Last Posted Date
- 2021-06-11
- Lead Sponsor
- Poxel SA
- Target Recruit Count
- 17
- Registration Number
- NCT03950882
- Locations
- πΊπΈ
High Point Clinical Trials Center, High Point, North Carolina, United States
Pharmacokinetics and Metabolism of (14C)-Labelled PXL770
- First Posted Date
- 2019-03-22
- Last Posted Date
- 2019-03-22
- Lead Sponsor
- Poxel SA
- Target Recruit Count
- 8
- Registration Number
- NCT03886103
- Locations
- π¬π§
Quotient, Nottingham, United Kingdom
Pharmacokinetics of Imeglimin in Hepatic Impaired Subjects
- First Posted Date
- 2019-01-14
- Last Posted Date
- 2020-08-11
- Lead Sponsor
- Poxel SA
- Target Recruit Count
- 14
- Registration Number
- NCT03802786
- Locations
- π©πͺ
Apex, Munich, Germany
A Study of the Efficacy and Safety of PXL770 Versus Placebo After 12 Weeks of Treatment in Patients With NAFLD
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2018-12-04
- Last Posted Date
- 2021-10-28
- Lead Sponsor
- Poxel SA
- Target Recruit Count
- 121
- Registration Number
- NCT03763877
- Locations
- πΊπΈ
Study Site 15, Orlando, Florida, United States
πΊπΈStudy Site 02, Los Angeles, California, United States
πΊπΈStudy Site 01, Gainesville, Florida, United States
Bioequivalence of Imeglimin Tablet Formulations
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2018-08-24
- Last Posted Date
- 2019-01-11
- Lead Sponsor
- Poxel SA
- Target Recruit Count
- 16
- Registration Number
- NCT03646331
- Locations
- π¬π§
Hammersmith Medicines Research (HMR), London, United Kingdom
Effect of Cimetidine on the PK of Imeglimin
- First Posted Date
- 2018-08-07
- Last Posted Date
- 2018-08-27
- Lead Sponsor
- Poxel SA
- Target Recruit Count
- 16
- Registration Number
- NCT03618316
- Locations
- π¬π§
Hammersmith Medicines Research (HMR), London, United Kingdom
Β© Copyright 2024. All Rights Reserved by MedPath